1Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496–509.
2Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370: 263–271.
3Voorhees JJ. Pathophysiology of psoriasis. Annu Rev Med 1977; 28: 467–473.
4Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 1979; 301: 555.
5Nicolas JF, Chamchick N, Thivolet J, Wijdenes J, Morel P, Revillard JP. CD4 antibodytreatment of severe psoriasis. Lancet 1991; 338: 321.
6Prinz J, Braun-Falco O, Meurer M, Daddona P, Reiter C, Rieber P et al. Chimaeric CD4monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 1991;338: 320–321.
7Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S et al. Blockade of Tlymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques,including the activation of keratinocytes, dendritic cells, and endothelial cells. J ExpMed 2000; 192: 681–694.
8Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Kinetics and regulation ofhuman keratinocyte stem cell growth in short-term primary ex vivo culture.Cooperative growth factors from psoriatic lesional T lymphocytes stimulateproliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J ClinInvest 1995; 95: 317–327.
